课题基金 / 基金详情

Role of cancer stem cells related molecules in oral squamous cell carcinoma

Role of cancer stem cells related molecules in oral squamous cell carcinoma
肿瘤干细胞相关分子在口腔鳞癌中的作用
批准号:
22592246
负责人:
YAMAZAKI Hiroshi
金额:
$2.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2010
资助国家:
日本
项目状态:
已结题
起止时间:
2010 至 2012

项目摘要

项目成果

YAMAZAKI Hiroshi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Oral squamous cell carcinoma (OSCC) include cellular heterogeneity, as would be expected if they arose from dysregulated stem or progenitor cells as opposed to the simple clonal expansion of a mutated cell; however, stemness molecule expression levels and distribution remain unclear. To overcome this problem, stemness molecule expressions were determined in OSCC as well as their properties and prognosis. Two chromatin regulators, Bmi-1 and Hmga2, were identified in 12 tumors region and background pair cases of OSCC by microarray. Both molecules are known to promote stem cell self-renewal by negatively regulating the expressions of Ink4a and Arf tumor suppressors. The expression levels were analyzed in 38 pair cases of OSCC by Qrt-PCR and in 91 cases of the same stage of tongue SCC. Despite a similar target, Bmi-1 protein was expressed in an early cancerous region and HMGA2 protein was expressed in a more progressed region. Likewise, Bmi1-expressing tumor had no significance with regard to overall survival (P = 0.67), while HMGA2-expressing tumors had decreased overall survival (P = 0.05). Qrt-PCR analyses also correlated with protein levels. These findings suggest that Bmi-1 is an early detection marker to distinguish cancerous from non-cancerous regions, while HMGA2 is presumed to be a tumor prognosis marker. Among our OSCC analyses, these stemness molecules expressed not so many primitive rare cells in the tumor as almost all other cells in the tumor. OSCC cells with high expression of stemness molecules should partially behave exactly like stem cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.yexcr.2012.09.013
发表时间: 2013-01-01
期刊: EXPERIMENTAL CELL RESEARCH
影响因子: 3.7
作者: [Effendi, Kathryn, Yamazaki, Ken, Sakamoto, Michiie]
通讯作者: Sakamoto, Michiie
DOI: 10.1016/j.joms.2012.03.031
发表时间: 2013
期刊: J Oral Maxillofac Surg.
影响因子: --
作者: [Yamazaki H, Ota Y, Aoki T, Kaneko A]
通讯作者: Kaneko A
DOI: 10.1016/j.tripleo.2011.08.026
发表时间: 2012
期刊: Oral Surg Oral Med Oral Pathol Oral Radiol
影响因子: --
作者: [Yamazaki H, Nakatogawa N, Ota Y, Karakida K, Otsuru M, Kaneko A, Shirasugi Y, Kajiwara H]
通讯作者: Kajiwara H
DOI: 10.1161/circresaha.109.205260
发表时间: 2010-05-28
期刊: CIRCULATION RESEARCH
影响因子: 20.1
作者: [Tsuji, Hiroko, Miyoshi, Shunichiro, Umezawa, Akihiro]
通讯作者: Umezawa, Akihiro
26
    Relevance to bioactivation and toxicity of thalidomide, pomalidomide, and lenalidomide by human cytochrome P450 3A enzymes in cultured placental cells and humanized-liver mice
    • 批准号:
      17K08425
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2017
    • 负责人:
      YAMAZAKI Hiroshi
    • 依托单位:
    Mechanisms of resistance to molecularly targeted drugs for oral squamous cell carcinoma and investigation of countermeasures
    • 批准号:
      16K11732
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2016
    • 负责人:
      YAMAZAKI Hiroshi
    • 依托单位:
    Development of Effective Markers for Resistance of Oral Squamous Cell Carcinoma to Molecular-targeting Drugs
    • 批准号:
      25463120
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.16万
    • 财政年份:
      2013
    • 负责人:
      YAMAZAKI Hiroshi
    • 依托单位:
    Thalidomide increases cytochrome P450 activity and drug metabolism in liver through direct activation of nuclear receptor CAR and PXR
    • 批准号:
      23590200
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.49万
    • 财政年份:
      2011
    • 负责人:
      YAMAZAKI Hiroshi
    • 依托单位:
    海外基金